Telix to acquire ITM in deal worth up to $2.35bn
ITM-11Positive
AI Analysis
Summary
Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich for up to $2.35 billion, combining Telix's operations with ITM's radioisotope production capabilities and late-stage treatment candidate ITM-11.
Outcome Details
Transaction valued at up to $2.35 billion
Importance:8/10
Sentiment:
0.70
M&Aacquisitionradioisotopelate-stage candidate
Related Companies
Read the original article
Published by Pharmaceutical Technology on September 21, 2026 9:13 AM